Andrew Bomback, MD, MPH

Discover which therapeutic targets and multicenter trial designs Columbia experts see as the next step for fibrillary glomerulonephritis research.

Explore how proteinuria targets and treatment decisions for non-responders differ across IgA nephropathy, lupus nephritis, and membranous nephropathy.

Understand how nonspecific therapy lowers cardiovascular risk in fibrillary glomerulonephritis and why transplant recurrence may be lower than reported.

Discover the four-drug conservative regimen one Columbia nephrologist uses to slow fibrillary glomerulonephritis progression without immunosuppression.

Explore when Columbia experts escalate to immunosuppression in fibrillary glomerulonephritis and how biopsy pattern shapes their choice of regimen.

Discover how Columbia experts rule out secondary causes and weigh the evidence for rituximab when fibrillary glomerulonephritis fails first-line therapy.

Andrew Bomback, MD, MPH, opens the segment by asking Gerald Appel, MD, how he defines a non-responder in fibrillary glomerulonephritis (FGN) in practice, how long patients should remain on therapy, and what numbers signal that treatment is not working.

Fibrillary glomerulonephritis (FGN) remains one of the least-studied glomerular diseases in nephrology, accounting for less than 1% of kidney biopsies and offering clinicians few evidence-based treatment options.

Bomback, MD, MPH answers HCPLive’s questions regarding phase 3 VALIANT results and pegcetacoplan’s therapeutic ability in C3G and IC-MPGN.

A trio of nephrology experts discuss the significance of iptacopan’s FDA approval as the first treatment for C3G.